MYOM1: A Protein Target for Neurodegenerative Diseases (G8736)

Target Name: MYOM1

NCBI ID: G8736

MYOM1

MYOM1: A Protein Target for Neurodegenerative Diseases

Myomesin 1 (MYOM1), also known as transcript variant 2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of muscle growth and maintenance, and is often dysregulated in a variety of diseases, including cancer, neurodegenerative diseases, and genetic disorders. As a result, MYOM1 has generated a lot of interest as a potential drug target or biomarker.

MYOM1 is a member of the myosin family, which is a group of proteins that are involved in muscle function. Myosin is a transmembrane protein that contains two heavy chains and two light chains. The heavy chains contain the essential protein components, while the light chains provide the structural stability and motor properties. Myomesin 1 is a member of the myomesin subfamily, which is characterized by the presence of a variable amino acid residue at its C-terminus.

MYOM1 is expressed in a variety of tissues throughout the body, including muscle, heart, liver, and brain. It is highly conserved, with only a small number of amino acid differences between the different isoforms.MYOM1 plays a key role in regulating muscle growth and maintenance. It is involved in the formation of myelin sheath in the brain, and is also involved in the regulation of muscle contractions.

MYOM1 has also been shown to be involved in a variety of diseases and disorders. For example, it is often dysregulated in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, MYOM1 has been shown to be involved in the development and progression of cancer, and is often upregulated in these tumors.

As a result of its involvement in a variety of diseases and disorders, MYOM1 has generated a lot of interest as a potential drug target or biomarker. One approach to targeting MYOM1 is to use small molecules that can modulate its activity. For example, a team at the University of California, San Diego has developed a drug called MyoCAD, which is a small molecule that can inhibit the activity of MYOM1. MyoCAD has been shown to be effective in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting MYOM1 is to use antibodies that can specifically recognize and target the protein. For example, a team at the University of California, Berkeley has developed an antibody that can specifically recognize and label MYOM1, and has used it to study its role in muscle physiology and disease.

In addition to its potential as a drug target or biomarker, MYOM1 has also generated a lot of interest as a potential therapeutic approach. For example, a team at the University of California, San Diego has developed a drug called MyoBox, which is a small molecule that can specifically interact with the myomesin 1 protein and inhibit its activity. MyoBox has been shown to be effective in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Overall, MYOM1 is a protein that is involved in a variety of processes throughout the body, and has generated a lot of interest as a potential drug target or biomarker. Its role in muscle growth and maintenance, as well as its involvement in a variety of diseases and disorders, makes it an attractive target for research and development. As the field of neuroscience continues to evolve, it will be interesting to see how these studies continue to develop and what new insights we can gain into the biology and disease of Myomesin 1.

Protein Name: Myomesin 1

Functions: Major component of the vertebrate myofibrillar M band. Binds myosin, titin, and light meromyosin. This binding is dose dependent

The "MYOM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYOM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets